Summary Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GCclamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P = 0.003).
p53 protein is a DNA-binding, cell-regulating transcription factor that has multiple critical roles in the complex pathway governing cell cycle and in the balance between cell division and apoptosis. Losses and/or mutations of p53 play a crucial role in a large number of malignancies.
The p53 gene is the most commonly mutated tumour-suppressor gene in various human cancers (Nigro et al, 1989) , and it has been reported in hepatocellular carcinomas (HCCs). However, most of these reports studied patients from east Asian countries and Africa, where viral hepatitis and aflatoxins are rather prevalent in contrast to Western countries. We examined 42 primary liver carcinoma specimens, which were surgically resected at the Hammersmith Hospital (UK) with histologically confirmed diagnosis, for mutation of the p53 gene by denaturing gradient gel electrophoresis (DGGE) , single-strand conformation polymorphism (SSCP) and sequence analysis.
The aim of this investigation was to study the presence of p53 mutation in HCC patients without viral hepatitis, such as those with the fibrolamellar variant, alcoholic cirrhosis or the classical non-cirrhotic HCC patients. In addition, we aimed to find out whether p53 mutation could influence survival after surgical resection in these patients.
PATIENTS AND METHODS
Forty-two patients with HCC were studied, of whom nine had the fibrolamellar variant of HCC. Eighteen of the 42 HCC patients had underlying cirrhosis (six alcoholic, 12 non-alcoholic). The 12 patients with non-alcoholic cirrhosis had serological evidence of viral infection (two were HBs antigen and HcVAb positive, seven were HCV antibody positive and three were HBs antigen and HCV antibody positive). The remaining 13 had non-cirrhotic HCC tumours. A further two patients had sarcomatoid transformation of hepatocellular carcinoma (Kakizoe et al, 1987) . The study included 14 women and 28 men with a mean age of 54.6 years (range 14-73 years). All patients underwent surgical resection of their tumours. None of the patients had any preoperative chemotherapy. Tumour tissue samples as well as surrounding non-tumorous liver tissue samples were obtained at the time of operation. The tissue samples were fixed in 10% neutral formalin and subjected to histopathological examination. A portion of each specimen was frozen in liquid nitrogen immediately after resection and stored at -70°C until DNA extraction. DNA was prepared from tissue specimens by standard phenol-chloroform methods (Sambrook et al, 1989) .
PCR amplification for the DGGE study Primers flanking p53 exon sequences were prepared according to the previous report (Beck et al, 1993 Figure 1 Exon 5 mutation 5. (A) Exon 5 PCR product SSCP analysis of cases 1 and 9 (C, control). (B) Direct sequencing. The T insertion (case 1) determines the shift of the sequencing pattern of the mutated allele (compare normal and tumoral sequences). In case 9, a C -* T transition produces a non-sense mutation. The homozygous state of case 9 is evident in both experimental approaches its standard 'potassium chloride' buffer. Samples were incubated in a DNA thermal cycler (GeneAmp PCR system 2400, PerkinElmer) for a total of 40 cycles at 94°C, 58°C, 72°C for 30 s at each temperature. Four microlitres of the polymerase chain reaction (PCR) products were subjected to electrophoresis on a 2% agarose gel to examine successful amplification of each fragment.
DGGE
The optimum gradient for each PCR product was determined with perpendicular DGGE according to the manufacturer's instructions (D-Gene Denaturing Gel Electrophoresis System, Bio-Rad). The ranges of denaturant of parallel DGGE and the optimum conditions of electrophoresis were previously reported (Beck et al, 1993) . Gels were stained with ethidium bromide and were photographed using Polaroid film.
PCR and single-strand conformation polymorphism analysis Primers for DNA amplification of the complete coding region, including exon-intron junctions, were appropriately selected from the human p53 gene sequence (Lamb and Crawford, 1986 ).
The reaction mixture contained 100 ng of genomic DNA, 30 pmol of appropriate oligonucleotide primer pairs, 0.1 mm dNTPs, 50 mm potassium chloride, 1.5 mm magnesium chloride, 10 mM Tris-HCI pH 9, 2.5 U of Taq DNA Pol (Pharmacia Biotech) in a total volume of 100 gl. In each set of PCR reactants, a negative no-template control was included. The amplified products were purified to eliminate primers and non-specific products on 2% agarose Tris-borate-EDTA (TBE) gel. The appropriate band was cut out from the gel and eluted by QlAquick Gel Extraction kit (Qiagen).
Five microlitres of PCR product (300 ng) were mixed with 2 gl of 1% sodium deoxycholate, 2 pl of EDTA 0.11 M pH 7.5 and 5 gl of loading buffer (deionized formamide 98%, 2 gl of EDTA 0.11 pl of bromophenol blue-xylene cyanol 0.3%). The samples were boiled for 5 min and immediately subjected to electrophoresis on non-denaturing polyacrylamide gel; 8 x 10 cm 0.75-thick polyacrylamide gels and 0.5 x TBE pH 7.5 running buffer were used. A constant internal buffer temperature was maintained during the gel run. Gels were run at 200 V for 1-4 h, depending on the fragment size and gel percentage.
After electrophoresis, the gels were silver stained and dried down. 
Sequence
Exons showing an altered migration in SSCP and DGGE were sequenced both with forward and reverse primers to confirm the mutations on both strands. When the tumour was identified to have a mutation, the p53 sequence of the non-tumorous liver tissue from the same individual was also evaluated. Sequence compression problems, as a result of the high G-C content in the gene, were solved by using modified nucleotides, such as deazanucleotides and inosine and controlled temperature conditions in electrophoretic running.
Sequencing primers were the same as those used for SSCP. A cycle-sequencing kit (Perkin Elmer) and [35Sd]ATP were used for sequencing. The products reaction was electrophoresed on a denaturing 6% polyacrylamide-7 M urea gel according to the manufacturer's instructions.
The survival data of all these patients after hepatectomy were collected prospectively and were analysed using the log-rank test.
RESULTS
Two patients (cases 1 and 9) had mutation in exon 5 as shown in the SSCP analysis ( Figure IA ). Direct sequencing showed that case no. 1 had a T insertion between residues 156 and 157 ( Figure  IB ). Sequencing analysis of case no. 9 showed a mutation of codon 136, CAA-TAA with a substitution from glutamine to a stop codon Figure 3A , cases 2, 3 and 10 had a heterozygous germline substitution both in the tumoral and non-tumoral tissue. Case 4, instead, had a homozygous mutation only in the tumoral liver.
The sequencing of cases 2 and 10 revealed two non-sense mutations in the tumoral tissue at codon 196 (Arg -< stop) and 204 (Glu -* stop), respectively ( Figure 3C ), besides the 213 polymorphism.
As for exon 7, three tumour samples (cases 5-7) showed deviated bands in SSCP analysis ( Figure 4A ). HaeIII analysis revealed that two of them (cases 6 and 7) had codon 249 mutation after the loss of the restriction site (data not shown). Sequence analysis showed a missense mutation AGG-AGT leading to amino acid substitution from arginine to serine ( Figure 4B ). Sequencing and HaeIII digestion suggest that case 6 had a mutation in the homozygous state. Case 5 had a missense mutation GGC-TGC leading to amino acid substitution from glycine to cysteine ( Figure 4B ).
British Journal of Cancer (1998) One tumour sample (case 8) showed a deviated band in exon 8 in DGGE (data not shown). Sequencing revealed that the patient had a non-sense mutation of codon 294 (Glu-stop) ( Figure 5) .
Of all the mutated samples, three showed a single mutant band in sequencing gel (cases 4, 6 and 9) which most probably represents a homozygous state resulting from the pairing of a mutant allele with a deletion in the remaining allele.
The homozygous state of case 4 was supported by Taq I digestion, of case 6 by HaeIII digestion (data not shown) and by SSCP, and of case 9 by SSCP.
In the remaining cases, the sequencing gels, the SSCP and the restriction analyses revealed both the mutant as well as the wild-type bands. These tumours may have a p53 mutation but no deletion of the remaining wild-type p53 allele, alternatively the wild-type band may be derived from the contamination of tumour DNA by the non-tumoral stroma or liver DNA.
The detected mutations were searched against the p53-specialized database (Hollstein et al, 1994) Survival data Survival data after liver resection showed that the mean and the median survival in patients with wild-type p53 were 60 and 43 months respectively. In the group with p53 mutation, the mean and median survival were 15 and 12 months. The difference was statistically significant (P = 0.0034) (Figure 6 ). The data for HCC patients with and without p53 mutations were also analysed, excluding those patients with the fibrolamellar variant. Survival in the HCC patients without mutations (median 43 months) was higher than that in patients with mutation (P = 0.0023).
DISCUSSION
In this study, a group of 42 patients was analysed. Ten patients showed somatic single nucleotide substitutions and two of them also showed a germline polymorphism (cases 2 and 10). All the mutations identified in our study were in the core domain, which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292) , critical for the biological activity of the protein.
In case 1, the mutation, never reported before, is a T insertion between residues 156 and 157 (exon 5 (Cho et al, 1994 (Cho et al, 1994 The type of mutation was assessed by sequencing.
The variant CGA-CGG silent third position alteration resulted in no amino acid changes. This variant was detected both in normal and in tumoral tissue and thus represents a naturally occurring germline polymorphism at codon 213. This polymorphism has been reported in literature and is estimated to occur in 3.5% of the worldwide population but is found in about 10% of the Italian population (Serra et al, 1992 (Cho et al, 1994) .
As far as the nucleotide substitution pattern, six are G-T transversions, two are C-T transitions and two are A-G transitions. G to T transversion is caused by both exogenous carcinogens and endogenous processes, such as free radical damage arising from normal biochemical reactions in mouse and monkey (Adelman et al, 1988) . Two mutations involve CpG pairs (residues 196 and 213) . CpG sites are preferential targets for point mutations in different mammalian genes during the process of DNA replication, presumably due to spontaneous deamination of methylated cytosine residues (Abadie et al, 1989 (Robinson, 1994) .
Indirect evidence suggests that most HCC may be a response to general effects of perisistent viral HBV and HCV infection of hepatocytes, which leads to chronic liver injury that initiates other events, including hepatocellular necrois, inflammatory response and hepatocellular proliferation associated with liver regeneration (necroinflammatory liver disease). The continuation of the necroinflammatory process for many years commonly leads to cirrhosis and therefore greatly increases the risk of HCC development. Regeneration of liver cells through chronic hepatitis increases the incidence of genetic alterations in hepatic cells and/or HCCs in both HBV-and HCV-infected patients.
A direct viral oncogenic mechanism has not been definitely established for any HCC in HBV-infected humans. However, it was reported that HBV may act as a non-selective insertional mutagenic agent. Indeed, chronic hepatitis B infections leads to viral integration, at random sites, into the hepatocyte DNA and is frequently associated with deletions, mutations and rearrangements of genomic DNA near the site of integration. Two HCCs have been reported with deletions in l7pl3 with loss of p53 and HBV integration at that site (Hino et al, 1986; Slagle et al, 1991) . Furthermore, after integration of viral DNA, overexpressed HBV gene products (HBx, MHBst) have the capacity to function as transcriptional transactivators. They may alter signal transduction pathways important for the regulation of cell growth during hepatocellular regeneration and compromise cellular DNA repair processes (Feitelson and Duan, 1997) . All these events contribute to genomic instability and to hepatocarcinogenesis.
There are many reports on the frequency of mutations of the p53 gene of HCC. High frequency of the mutation at codon 249 in exon 7 was reported from China (Hsu et al, 1991) and South Africa (Bressac et al, 1991) , where patients were exposed to high levels of aflatoxin B (AFB 1). In our study, only two HCCs had this specific mutation. In Japan, Nose et al (1990) reported that alterations associated with the p53 gene were found in 6 of 20 HCCs (30%). Likewise, Nishida et al (1993) , and Hayashi et al (1995) also reported that the frequency was 32% and 27.8%, respectively, in Japan. No mutational hot spot has been reported in these studies, suggesting the involvement of different aetiological factors from AFB 1. Buetow et al (1992) analysed 107 HCCs from geographically and ethnically diverse sources. They reported that the mutation rate of tumours from high AFB 1-exposure regions was 25% and that in low-exposure regions was 12%. In our study, the overall mutation rate was 22%. However, the mutation rate of the HCCs with cirrhosis due to viral hepatitis was very high (66%). Hosono et al (1991) reported infrequent mutation of the p53 gene (18%) in hepatitis B virus-positive primary HCCs from Taiwan. Shieh et al (1993) also suggested that p53 mutations may not play a significant role in HCV-or HBV-associated hepatocarcinogenesis. However, Teramoto et al (1994) reported that patients infected with either HBV or HCV showed an incidence of p53 abnormalities (45%) higher than those infected by neither (13% (Ding et al, 1993a) . Both patients had large undifferentiated tumours, extensive local invasion and local recurrence and both died within 6 months of the operation from multiple lung metastases. It is quite likely that the p53 gene was also involved in these multiple genetic changes that led to the poor outcome in these two patients. Fibrolamellar carcinoma is a rare variant of hepatocellular carcinoma (HCC). It occurs in younger patients (aged 20-30 years) with an equal sex incidence. Cirrhosis and hepatitis B and C viruses are rarely seen in patients with FLC, and it is thought that the tumour may arise from areas of focal nodular hyperplasia (Vecchio et al, 1984) . The prognosis of patients with FLC is better than that of those with HCC. All the patients in this series with this variant who were operated are still alive and none of them have p53 mutations. This is in contrast to the two patients with sarcomatoid changes and with p53 mutations, both died of tumour recurrence within 6 months. Previously, in a loss of heterozygosity study using 25 RFLP probes for chromosomes 1-5, 7, 9, 11-14, 16 -18 and 20 we found 3.6% allele loss in fibrolamellar HCC (Ding et al, 1993b) vs 16.1% cirrhotic and non-cirrhotic HCC (Ding et al, 1991) and 56.2% in sarcomatoid HCC (Ding et al, 1993a) .
There are several reports on the relationship between mutations of the p53 gene and poorer prognosis. Hayashi et al (1995) reported that the presence of p53 mutations in HCCs was associated with a shortened cancer-free survival and a shortened survival.
Likewise, in this study, we found p53 to be a poor prognostic indicator for survival in patients undergoing liver resection. Future studies may show that tumour staging could include the preoperative determination of p53 status in these patients. The presence of p53 mutation might discourage surgeons to consider resection and might be a favourable criteria for inclusion in gene replacement therapy (Habib et al, 1996) .
In this study, DGGE was more reliable than SSCP in detecting p53 mutations. All four patients with exon 6 mutations were missed by SSCP. On the other hand DGGE and SSCP were equally sensitive in identifying all patients with mutations in exons 5, 7, 8 and 9. To streamline experiments for exons 1-4 10 and 11, only SSCP was used.
In conclusion, p53 mutations occur mainly in the group of HCC patients with liver cirrhosis associated with viral hepatitis and is a poor prognostic indicator for survival after liver resection.
